Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · Real-Time Price · USD

21.71

-0.50 (-2.25%)

At close: Mar 12, 2026, 4:00 PM EDT

21.51

-0.20 (-0.92%)

Pre-market: Mar 13, 2026, 6:00 AM EDT

Ultragenyx Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	421	174	213.58	132.94	307.58
Short-Term Investments	259	436	363.63	614.82	432.61
Cash & Short-Term Investments	680	610	577.21	747.76	740.2
Cash Growth	11.47%	5.68%	-22.81%	1.02%	-38.40%
Accounts Receivable	158	122	73.39	40.45	28.43
Inventory	52	45	33.97	26.77	16.23
Other Current Assets	61	40	47.62	68.93	71.75
Total Current Assets	951	817	732.18	883.9	856.6
Net Property, Plant & Equipment	244	266	290.57	259.73	176.18
Other Intangible Assets	176	178	166.27	160.11	130.79
Goodwill	44	44	44.41	44.41	44.41
Long-Term Investments	57	135	199.9	148.97	293.86
Other Long-Term Assets	60	63	57.69	48.34	20.56
Total Assets	1,532	1,503	1,491	1,545	1,522
Accounts Payable	31	39	42.11	43.27	17.14
Accrued Expenses	265	241	196.49	204.68	145.56
Current Portion of Leases	12	10	12.6	11.78	11.07
Unearned Revenue	-	-	-	1.48	7.61
Other Current Liabilities	76	54	29.24	-	-
Total Current Liabilities	384	344	280.44	261.21	181.37
Long-Term Leases	24	30	30.57	19.81	30.9
Other Long-Term Liabilities	1,197	867	904.59	911.93	387.56
Total Long-Term Liabilities	1,221	897	935.16	931.74	418.47
Total Liabilities	1,605	1,241	1,216	1,193	599.84
Common Stock	8	4	0.08	0.07	0.07
Treasury Stock	-8	-4	-0.43	-	-
Additional Paid-in Capital	4,451	4,213	3,662	3,140	2,997
Accumulated Other Comprehensive Income	1	-1	1.08	-6.57	-1.4
Retained Earnings	-4,532	-3,957	-3,388	-2,781	-2,074
Total Common Shareholders' Equity	-80	255	275.41	352.49	922.56
Minority Interest	7	7	-	-	-
Shareholders' Equity	-73	262	275.41	352.49	922.56
Total Liabilities & Equity	1,532	1,503	1,491	1,545	1,522
Total Debt	36	40	43.17	31.59	41.97
Net Cash (Debt)	644	570	534.04	716.17	698.23
Net Cash Growth	12.98%	6.73%	-25.43%	2.57%	-39.46%
Net Cash Per Share	6.53	6.30	7.27	10.24	10.30
Book Value	-80	255	275.41	352.49	922.56
Book Value Per Share	-0.81	2.82	3.75	5.04	13.61
Tangible Book Value	-300	33	64.74	147.98	747.37
Tangible Book Value Per Share	-3.04	0.36	0.88	2.12	11.02

Updated Feb 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q